All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
SHANGHAI – Ascentage Pharma Group and its pipeline of small-molecule, apoptosis-targeted cancer agents has bagged $15.5 million in a series A round from a group of Chinese venture investors.
